Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat mesylate alone and in combination for advanced solid tumors
ChiCTR2500101668Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of purinostat in Nonhematologic neoplasms, breast cancer, non-small cell lung cancer (NSCLC) and 8 more (6 cohorts), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoints: Objective response rate, Disease control rate and 4 more. Started Apr 2025; status: recruiting.
02
Drugs
purinostat
03
Conditions
Nonhematologic neoplasmsbreast cancernon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2500101668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101668.